Search

Your search keyword '"Trpkov, Kiril"' showing total 775 results
Start Over Author "Trpkov, Kiril"
775 results on '"Trpkov, Kiril"'

201. Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.

Author

Aldaoud, Najla, Abdo, Nour, Al Bashir, Samir, Alqudah, Mohammad, Marji, Noor, Alzou'bi, Hiba, Alazab, Rami, and Trpkov, Kiril

Abstract

TMPRSS2/ERG fusion was found to be the most common genetic event in prostate adenocarcinoma. There is a strong correlation between the fusion and ERG-positive immunostaining. Many studies showed racial variation in ERG expression in prostate cancer patients. There is no data however on the rate of ERG-positive cancer in Jordanian or Arab population. We evaluated the frequency and the significance of ERG fusion in Jordanian-Arab population using immunohistochemistry for ERG. The cohort included 193 prostate cancer specimens: 109 needle core biopsies, 45 radical prostatectomies, 37 transurethral resections of prostate, and 2 enucleation specimens. We found ERG reactivity in 64 (33.2%) of evaluated cases. The observed ERG frequency in the Jordanian-Arab population is lower than the one documented in North America, but it is higher than in Asian patient cohorts. The ERG positivity was significantly associated with lower baseline prostate-specific antigen but was unrelated to patient age, Gleason Score, or the novel Gleason Grade Groups. In the 45 prostatectomy cases, ERG did not correlate with the pathologic stage, margin, nodal status, and the biochemical recurrence, and it did not appear to represent an important prognosticator. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

202. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.

Author

Alaghehbandan, Reza, Stehlik, Jan, Trpkov, Kiril, Magi-Galluzzi, Cristina, Condom Mundo, Enric, Pane Foix, Maria, Berney, Daniel, Sibony, Mathilde, Suster, Saul, Agaimy, Abbas, Montiel, Delia Perez, Pivovarcikova, Kristyna, Michalova, Kvetoslava, Daum, Ondrej, Ondic, Ondrej, Rotterova, Pavla, Dusek, Martin, Hora, Milan, Michal, Michal, and Hes, Ondrej

Abstract

Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13 FH-RCCs collected in an international multi-institutional study, were evaluated by immunohistochemistry (IHC) for PD-1/PD-L1 reactivity in tumor cells and tumor infiltrating lymphocytes (TILs). PD-1/PD-L1 expression was further evaluated by qPCR. By IHC, PD-1 was negative in tumor cells in all 13 cases. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively. In TILs, PD-1 was positive in 1/13, weak positive in 3/13, and negative in 9/13 cases. In TILs, PD-L1 was weak positive by IHC in 5/13, and negative in 8/13 cases, respectively. qPCR confirmed the result for 2 of 3 IHC weak positive PD-1 samples. Of 7 IHC weak positive samples (in tumor cells), PD-L1 mRNA was detected in all 7 tumors. The majority of FH-RCCs did not express PD-1/PD-L1 by IHC, which was confirmed by molecular analysis. PD-1/PD-L1 expression in FH-RCC is restricted to a proportion of cases which may benefit from targeted therapies. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

203. Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer.

Author

Kryvenko, Oleksandr, Williamson, Sean, Jorda, Merce, Trpkov, Kiril, Athanazio, Daniel, Gupta, Nilesh, Selig, Martin, Smith, Paul, Magi-Galluzzi, Cristina, Kryvenko, Oleksandr N, Williamson, Sean R, Gupta, Nilesh S, Selig, Martin K, and Smith, Paul Taylor

Abstract

Small cell-like change (SCLC) is a rare prostate lesion which has been described in only two previous studies (total of eight cases). Its relation to possible neuroendocrine differentiation remained unclear. We evaluated 11 SCLC cases with immunohistochemistry and electron microscopy. SCLC was characterized by crowded hyperchromatic small nuclei with scant cytoplasm, rosette-like structures, finely granular chromatin with indistinct nucleoli, and lack of mitoses, apoptoses, and necroses. In nine cases, SCLC was admixed with high-grade cancer, and in two cases, it represented a separate intraductal process, spatially remote from a low-volume Gleason score 6 (grade group 1) cancer. Only 2/11 SCLC labeled for synaptophysin, chromogranin, and serotonin, although 6/11 were at least focally positive for TTF1. Staining for NKX3.1 and pancytokeratin was typically weak, focal, and markedly reduced compared to the adjacent cancer. SCLC was positive for ERG in 1/8 and for racemase in 6/10 cases, again typically in a focal and weak fashion. There was no immunoreactivity with CD56, p63, or HMWCK. Ki-67 highlighted only rare nuclei (<1 %). No neuroendocrine granules were demonstrated by electron microscopy in four cases that showed no immunoreactivity for neuroendocrine markers. In summary, SCLC is more frequently found in high-grade prostate cancer, but it may also be encountered as a noninvasive lesion in Gleason score 6 (grade group 1) cancer. Importantly, it does not appear to indicate neuroendocrine differentiation. The low-grade cytology, the lack of mitoses and apoptoses, and the minimal Ki-67 reactivity are findings to support its discrimination from a small cell carcinoma. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

204. Les tumeurs rénales : recommandations de la conférence de consensus de l’International Society of Urologic Pathology (ISUP) 2012

Author

Rioux-Leclercq, Nathalie, primary, Ferran, Algaba, additional, Mahul, Amin, additional, Argani, Pedram, additional, Billis, Athanase, additional, Bonsib, Stephen, additional, Cheng, Liang, additional, Cheville, John, additional, Eble, John, additional, Egevad, Lars, additional, Epstein, Jonathan, additional, Grignon, David, additional, Hes, Ondrej, additional, Humphrey, Peter, additional, Magi-Galluzzi, Cristina, additional, Martignoni, Guido, additional, McKenney, Jesse, additional, Merino, Maria, additional, Moch, Holger, additional, Montironi, Rodolfo, additional, Netto, George, additional, Reuter, Viktor, additional, Samaratunga, Hemamali, additional, Shen, Steven, additional, Srigley, John, additional, Tamboli, Pheroze, additional, Tan, Puay Hoon, additional, Tickoo, Satish, additional, Trpkov, Kiril, additional, Zhou, Ming, additional, Delahunt, Brett, additional, and Comperat, Eva, additional

Published
2014
Full Text
View/download PDF

205. Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma

Author

Gill, Anthony J., primary, Hes, Ondrej, additional, Papathomas, Thomas, additional, Šedivcová, Monika, additional, Tan, Puay Hoon, additional, Agaimy, Abbas, additional, Andresen, Per Arne, additional, Kedziora, Andrew, additional, Clarkson, Adele, additional, Toon, Christopher W., additional, Sioson, Loretta, additional, Watson, Nicole, additional, Chou, Angela, additional, Paik, Julie, additional, Clifton-Bligh, Roderick J., additional, Robinson, Bruce G., additional, Benn, Diana E., additional, Hills, Kirsten, additional, Maclean, Fiona, additional, Niemeijer, Nicolasine D., additional, Vlatkovic, Ljiljana, additional, Hartmann, Arndt, additional, Corssmit, Eleonora P.M., additional, van Leenders, Geert J.L.H., additional, Przybycin, Christopher, additional, McKenney, Jesse K., additional, Magi-Galluzzi, Cristina, additional, Yilmaz, Asli, additional, Yu, Darryl, additional, Nicoll, Katherine D., additional, Yong, Jim L., additional, Sibony, Mathilde, additional, Yakirevich, Evgeny, additional, Fleming, Stewart, additional, Chow, Chung W., additional, Miettinen, Markku, additional, Michal, Michal, additional, and Trpkov, Kiril, additional

Published
2014
Full Text
View/download PDF

206. Tuberous Sclerosis–associated Renal Cell Carcinoma

Author

Guo, Juan, primary, Tretiakova, Maria S., additional, Troxell, Megan L., additional, Osunkoya, Adeboye O., additional, Fadare, Oluwole, additional, Sangoi, Ankur R., additional, Shen, Steven S., additional, Lopez-Beltran, Antonio, additional, Mehra, Rohit, additional, Heider, Amer, additional, Higgins, John P., additional, Harik, Lara R., additional, Leroy, Xavier, additional, Gill, Anthony J., additional, Trpkov, Kiril, additional, Campbell, Steven C., additional, Przybycin, Christopher, additional, Magi-Galluzzi, Cristina, additional, and McKenney, Jesse K., additional

Published
2014
Full Text
View/download PDF

207. Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology

Author

Amin, Mahul B., primary, Epstein, Jonathan I., additional, Ulbright, Thomas M., additional, Humphrey, Peter A., additional, Egevad, Lars, additional, Montironi, Rodolfo, additional, Grignon, David, additional, Trpkov, Kiril, additional, Lopez-Beltran, Antonio, additional, Zhou, Ming, additional, Argani, Pedram, additional, Delahunt, Brett, additional, Berney, Daniel M., additional, Srigley, John R., additional, Tickoo, Satish K., additional, and Reuter, Victor E., additional

Published
2014
Full Text
View/download PDF

212. VSTM2AOverexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney

Author

Wang, Lisha, Zhang, Yuping, Chen, Ying-Bei, Skala, Stephanie L., Al-Ahmadie, Hikmat A., Wang, Xiaoming, Cao, Xuhong, Veeneman, Brendan A., Chen, Jin, Cieślik, Marcin, Qiao, Yuanyuan, Su, Fengyun, Vats, Pankaj, Siddiqui, Javed, Xiao, Hong, Sadimin, Evita T., Epstein, Jonathan I., Zhou, Ming, Sangoi, Ankur R., Trpkov, Kiril, Osunkoya, Adeboye O., Giannico, Giovanna A., McKenney, Jesse K., Argani, Pedram, Tickoo, Satish K., Reuter, Victor E., Chinnaiyan, Arul M., Dhanasekaran, Saravana M., and Mehra, Rohit

Abstract

Supplemental Digital Content is available in the text.Our recent study revealed recurrent chromosomal losses and somatic mutations of genes in the Hippo pathway in mucinous tubular and spindle cell carcinoma (MTSCC). Here, we performed an integrative analysis of 907 renal cell carcinoma (RCC) samples (combined from The Cancer Genome Atlas and in-house studies) and the Knepper data set of microdissected rat nephrons. We identified VSTM2Aand IRX5as novel cancer-specific and lineage-specific biomarkers in MTSCC. We then assessed their expression by RNA in situ hybridization (ISH) in 113 tumors, including 33 MTSCC, 40 type 1 papillary RCC, 8 type 2 papillary RCC, 2 unclassified RCC, 15 clear cell RCC, and 15 chromophobe RCC. Sensitivity and specificity were calculated as the area under the receiver operating characteristics curve (AUC). All MTSCC tumors demonstrated moderate to high expression of VSTM2A(mean ISH score=255). VSTM2Agene expression assessed by RNA sequencing strongly correlated with VSTM2AISH score (r2=0.81, P=0.00016). The majority of non-MTSCC tumors demonstrated negative or low expression of VSTM2A. IRX5, nominated as a lineage-specific biomarker, showed moderate to high expression in MTSCC tumors (mean ISH score=140). IRX5gene expression assessed by RNA sequencing strongly correlated with IRX5ISH score (r2=0.69, P=0.00291). VSTM2A(AUC: 99.2%) demonstrated better diagnostic efficacy than IRX5(AUC: 87.5%), and may thus serve as a potential diagnostic marker to distinguish tumors with overlapping histology. Furthermore, our results suggest MTSCC displays an overlapping phenotypic expression pattern with the loop of Henle region of normal nephrons.

Published
2018
Full Text
View/download PDF

213. Concordance of “Case Level” Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy

Author

Trpkov, Kiril, Sangkhamanon, Sakkarn, Yilmaz, Asli, Medlicott, Shaun A.C., Donnelly, Bryan, Gotto, Geoffrey, and Shea-Budgell, Melissa

Abstract

Supplemental Digital Content is available in the text.The practice of assigning “case level” biopsy Grade Group (GG) or Gleason Score is variable. To our knowledge, a comparison of the concordance of different biopsy “case level” GG with the prostatectomy GG has not been done in a post-2005 prostate cancer cohort. We evaluated the GG in 2527 patients who had biopsy and radical prostatectomy performed at our institution between 2005 and 2014. We compared the agreements, the upgrades, and the downgrades of 3 different “case level” biopsy GG, with the final GG: (1) Global GG (sum of most prevalent and highest Gleason grade in any biopsy part/site-specific specimen); (2) Highest GG (found in any biopsy part/site-specific specimen); and (3) Largest Volume Cancer GG (found in any biopsy part/site-specific specimen). The concordance between the biopsy and the final GG were evaluated using weighted kappa (κ) coefficient. The biopsy Global GG, Highest GG, and Largest Volume Cancer GG were the same as the final GG in 60.4%, 57.1%, and 54.3% cases, respectively (weighted κ values: 0.49, 0.48, and 0.44, respectively). When final GG contained tertiary 5, the overall GG agreement decreased: Global GG 41.5%, Highest GG 40.3%, and Largest Volume Cancer GG 37.1% (weighted κ: 0.22, 0.21, and 0.18, respectively). A subset analysis for cases in which the biopsy Global GG and Highest GG were different (n=180) showed an agreement of 62.4% (weighted κ: 0.37) and 18.8% (weighted κ: 0.16), respectively. In patients without a tertiary Gleason pattern on radical prostatectomy, the Global GG and the Highest GG were identical in 92.4% of biopsies. Assigning a biopsy “case level” Global GG versus using the Highest GG and the Largest Volume Cancer GG resulted in comparable and slightly improved agreement with the final GG in this cohort.

Published
2018
Full Text
View/download PDF

214. Challenges in Pathologic Staging of Renal Cell Carcinoma

Author

Williamson, Sean R., Rao, Priya, Hes, Ondrej, Epstein, Jonathan I., Smith, Steven C., Picken, Maria M., Zhou, Ming, Tretiakova, Maria S., Tickoo, Satish K., Chen, Ying-Bei, Reuter, Victor E., Fleming, Stewart, Maclean, Fiona M., Gupta, Nilesh S., Kuroda, Naoto, Delahunt, Brett, Mehra, Rohit, Przybycin, Christopher G., Cheng, Liang, Eble, John N., Grignon, David J., Moch, Holger, Lopez, Jose I., Kunju, Lakshmi P., Tamboli, Pheroze, Srigley, John R., Amin, Mahul B., Martignoni, Guido, Hirsch, Michelle S., Bonsib, Stephen M., and Trpkov, Kiril

Abstract

Supplemental Digital Content is available in the text.Staging criteria for renal cell carcinoma differ from many other cancers, in that renal tumors are often spherical with subtle, finger-like extensions into veins, renal sinus, or perinephric tissue. We sought to study interobserver agreement in pathologic stage categories for challenging cases. An online survey was circulated to urologic pathologists interested in kidney tumors, yielding 89% response (31/35). Most questions included 1 to 4 images, focusing on: vascular and renal sinus invasion (n=24), perinephric invasion (n=9), and gross pathology/specimen handling (n=17). Responses were collapsed for analysis into positive and negative/equivocal for upstaging. Consensus was regarded as an agreement of 67% (2/3) of participants, which was reached in 20/33 (61%) evaluable scenarios regarding renal sinus, perinephric, or vein invasion, of which 13/33 (39%) had ≥80% consensus. Lack of agreement was especially encountered regarding small tumor protrusions into a possible vascular lumen, close to the tumor leading edge. For gross photographs, most were interpreted as suspicious but requiring histologic confirmation. Most participants (61%) rarely used special stains to evaluate vascular invasion, usually endothelial markers (81%). Most agreed that a spherical mass bulging well beyond the kidney parenchyma into the renal sinus (71%) or perinephric fat (90%) did not necessarily indicate invasion. Interobserver agreement in pathologic staging of renal cancer is relatively good among urologic pathologists interested in kidney tumors, even when selecting cases that test the earliest and borderline thresholds for extrarenal extension. Disagreements remain, however, particularly for tumors with small, finger-like protrusions, closely juxtaposed to the main mass.

Published
2018
Full Text
View/download PDF

215. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase–deficient Renal Cell Carcinoma

Author

Ohe, Chisato, Smith, Steven C., Sirohi, Deepika, Divatia, Mukul, de Peralta-Venturina, Mariza, Paner, Gladell P., Agaimy, Abbas, Amin, Mitual B., Argani, Pedram, Chen, Ying-Bei, Cheng, Liang, Colecchia, Maurizio, Compérat, Eva, Werneck da Cunha, Isabela, Epstein, Jonathan I., Gill, Anthony J., Hes, Ondřej, Hirsch, Michelle S., Jochum, Wolfram, Kunju, Lakshmi P., Maclean, Fiona, Magi-Galluzzi, Cristina, McKenney, Jesse K., Mehra, Rohit, Nesi, Gabriella, Osunkoya, Adeboye O., Picken, Maria M., Rao, Priya, Reuter, Victor E., de Oliveira Salles, Paulo Guilherme, Schultz, Luciana, Tickoo, Satish K., Tomlins, Scott A., Trpkov, Kiril, and Amin, Mahul B.

Abstract

Supplemental Digital Content is available in the text.Renal medullary carcinomas (RMCs) and collecting duct carcinomas (CDCs) are rare subsets of lethal high-stage, high-grade distal nephron-related adenocarcinomas with a predilection for the renal medullary region. Recent findings have established an emerging group of fumarate hydratase (FH)-deficient tumors related to hereditary leiomyomatosis and renal cell carcinoma (HLRCC-RCCs) syndrome within this morphologic spectrum. Recently developed, reliable ancillary testing has enabled consistent separation between these tumor types. Here, we present the clinicopathologic features and differences in the morphologic patterns between RMC, CDC, and FH-deficient RCC in consequence of these recent developments. This study included a total of 100 cases classified using contemporary criteria and ancillary tests. Thirty-three RMCs (SMARCB1/INI1-deficient, hemoglobinopathy), 38 CDCs (SMARCB1/INI1-retained), and 29 RCCs defined by the FH-deficient phenotype (FH−/2SC+or FH±/2SC+with FHmutation, regardless of HLRCC syndromic stigmata/history) were selected. The spectrum of morphologic patterns was critically evaluated, and the differences between the morphologic patterns present in the 3 groups were analyzed statistically. Twenty-five percent of cases initially diagnosed as CDC were reclassified as FH-deficient RCC on the basis of our contemporary diagnostic approach. Among the different overlapping morphologic patterns, sieve-like/cribriform and reticular/yolk sac tumor–like patterns favored RMCs, whereas intracystic papillary and tubulocystic patterns favored FH-deficient RCC. The tubulopapillary pattern favored both CDCs and FH-deficient RCCs, and the multinodular infiltrating papillary pattern favored CDCs. Infiltrating glandular and solid sheets/cords/nested patterns were not statistically different among the 3 groups. Viral inclusion–like macronucleoli, considered as a hallmark of HLRCC-RCCs, were observed significantly more frequently in FH-deficient RCCs. Despite the overlapping morphology found among these clinically aggressive infiltrating high-grade adenocarcinomas of the kidney, reproducible differences in morphology emerged between these categories after rigorous characterization. Finally, we recommend that definitive diagnosis of CDC should only be made if RMC and FH-deficient RCC are excluded.

Published
2018
Full Text
View/download PDF

216. Benign mimics of prostatic adenocarcinoma

Author

Trpkov, Kiril

Abstract

Benign mimics present either as common challenges in daily routine practice or may cause diagnostic dilemmas because some are less commonly seen and one may be less familiar in recognizing them. There are a multitude of mimics of prostatic adenocarcinoma, which may represent normal gland structures, benign proliferations, atrophic lesions, hyperplastic or metaplastic changes, and inflammatory processes. Some of them are preferentially found in certain anatomic areas of the prostate, either confined to the prostate, or outside of the gland. Various benign mimics of prostatic carcinoma may be also evaluated based on their morphologic similarity to Gleason patterns 3–5 of prostatic adenocarcinoma. Most of the mimics are easily recognizable in larger specimens, such as TUR of the prostate or radical prostatectomy specimens, but they may pose diagnostic problems when the evaluation is done on limited tissue, such as needle-core biopsies or if prostate specimens are infrequently encountered in practice. Therefore, before signing out a report with a diagnosis of prostatic carcinoma, pathologists should carefully consider and rule out the various benign lesions that may mimic carcinoma. This is particularly relevant in the current prostate biopsy practice which relies on using extended biopsy core templates. The awareness and familiarity with the characteristic features of the mimics and judicial use of additional ancillary tests, including immunohistochemistry can prevent overdiagnosis and false-positive interpretation. This review provides a contemporary update on the broad spectrum of the benign prostatic lesions that can mimic prostate adenocarcinoma, outlines their key morphologic and immunohistochemical diagnostic features, and provides a diagnostic, pattern-based approach in establishing a correct diagnosis and distinguishing them reliably from prostatic adenocarcinoma.

Published
2018
Full Text
View/download PDF

219. A tribute to Prof. Ondrej Hes, MD, PhD (1968–2022)

Author

Alaghehbandan, Reza, Agaimy, Abbas, Ali, Leila, Alvarado-Cabrero, Isabel, Amin, Mahul B., Boudova, Ludmila, Caliò, Anna, Comperat, Eva M., Damjanov, Ivan, Daum, Ondrej, Farcas, Mihaela, Gatalica, Zoran, Gill, Anthony J., Hartmann, Arndt, Hayes, Malcolm M., Hora, Milan, Kojima, Fumiyoshi, Kristiansen, Glen, Kuroda, Naoto, López, José I., Maclean, Fiona, Magi-Galluzzi, Cristina, Martignoni, Guido, McKenney, Jesse K., Michalová, Květoslava, Michal, Michael, Mohanty, Sambit K., Netto, George J., Ohashi, Riuko, Ondič, Ondrej, Osunkoya, Adeboye O., Gomez, María Delia Perez Montiel, Petersson, Fredrik, Picken, Maria M., Pivovarcikova, Kristyna, Rogala, Joanna, Shah, Rajal B., Siadat, Farshid, Skenderi, Faruk, Sperga, Maris, Suster, Saul M., Svajdler, Marian, Tretiakova, Maria, Trpkov, Kiril, Ulamec, Monika, Williamson, Sean R., Yang, Ximing J., Zhou, Ming, Vranic, Semir, Vujanic, Gordan, and Michal, Michal

Published
2022
Full Text
View/download PDF

220. Handling and Staging of Renal Cell Carcinoma

Author

Trpkov, Kiril, primary, Grignon, David J., additional, Bonsib, Stephen M., additional, Amin, Mahul B., additional, Billis, Athanase, additional, Lopez-Beltran, Antonio, additional, Samaratunga, Hemamali, additional, Tamboli, Pheroze, additional, Delahunt, Brett, additional, Egevad, Lars, additional, Montironi, Rodolfo, additional, and Srigley, John R., additional

Published
2013
Full Text
View/download PDF

222. Inflammasome-Independent NLRP3 Augments TGF-β Signaling in Kidney Epithelium

Author

Wang, Wenjie, primary, Wang, Xiangyu, additional, Chun, Justin, additional, Vilaysane, Akosua, additional, Clark, Sharon, additional, French, Gabrielle, additional, Bracey, Nathan A., additional, Trpkov, Kiril, additional, Bonni, Shirin, additional, Duff, Henry J., additional, Beck, Paul L., additional, and Muruve, Daniel A., additional

Published
2013
Full Text
View/download PDF

223. Solid papillary renal cell carcinoma: clinicopathologic, morphologic, and immunohistochemical analysis of 10 cases and review of the literature.

Author

Ulamec, Monika, Skenderi, Faruk, Trpkov, Kiril, Kruslin, Bozo, Vranic, Semir, Bulimbasic, Stela, Trivunic, Sandra, Montiel, Delia Perez, Peckova, Kvetoslava, Pivovarcikova, Kristyna, Ondic, Ondrej, Daum, Ondrej, Rotterova, Pavla, Dusek, Martin, Hora, Milan, Michal, Michal, and Hes, Ondrej

Abstract

Copyright of Annals of Diagnostic Pathology is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2016
Full Text
View/download PDF

224. Malakoplakia associated with prostatic adenocarcinoma: Report of 4 cases and literature review.

Author

Medlicott, Shaun, Magi-Galluzzi, Cristina, Jimenez, Rafael E., and Trpkov, Kiril

Abstract

Malakoplakia is an inflammatory process that has been rarely reported in the prostate. Malakoplakia in association with prostatic carcinoma is exceedingly rare with only 4 previously reported cases. We describe the clinical features and the associated pathology in 4 patients who demonstrated malakoplakia of the prostate in association with prostatic adenocarcinoma. Prostatic malakoplakia presenting in association with prostatic adenocarcinoma was identified in 4 patients through a search from the records of 3 institutional databases with large in-house and consult uropathology practices. In 2 of the patients the diagnostic needle biopsy contained only prostatic carcinoma; malakoplakia in association with prostatic carcinoma was documented on prostatectomy, performed 15 and 8 weeks after the biopsy, respectively. Both patients experienced urinary infections during the interval between the biopsy and the prostatectomy. The third and fourth patient had a long-standing history of “prostatitis”, and acute urinary tract infection with urinary retention, respectively. The needle biopsy in both patients showed concomitant malakoplakia and prostatic carcinoma. One of them also had malakoplakia on the initial biopsy containing only atypical glands and on the subsequent one demonstrating carcinoma. One patient was treated conservatively and one with prostatectomy. Although coexistent prostatic carcinoma and malakoplakia are exceedingly rare, malakoplakia can likely occur as an exceptionally rare complication of a prostate needle biopsy, particularly in individuals with long-term or acute urinary tract infections at the time of the biopsy. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

225. Handling, sampling and stage evaluation of renal cell carcinoma: A practical guide.

Author

Bonert, Michael, Huang, Kuo-Cheng, and Trpkov, Kiril

Abstract

Tumor stage is considered the single most important prognostic factor in renal cell carcinoma. The most critical issue when determining the pathologic stage is whether the tumor is organ-confined or has spread outside of the organ and invaded the perinephric tissues and the adjacent structures. Proper handling and sampling of nephrectomy specimens is essential for accurate determination of pathologic stage and other relevant tumor parameters. Tumor staging requires careful assessment of various tumor characteristics, including tumor size, extent of tumor invasion in relation to specific kidney structures (sinus fat, renal vein and its segmental branches) and perinephric tissues (perinephric fat, Gerota fascia, adrenal gland and vena cava). Therefore, it is imperative that pathologists are familiar with the normal renal anatomy and histology, able to properly dissect surgically resected renal tumors, and able to assess specimens grossly and microscopically, to accurately determine and report pathologic stage and other relevant tumor parameters. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

226. ABCC2 brush‐border expression predicts outcome in papillary renal cell carcinoma: a multi‐institutional study of 254 cases.

Author

Castillo, Vincent Francis, Masoomian, Mehdi, Trpkov, Kiril, Downes, Michelle, Brimo, Fadi, van der Kwast, Theodorus, Yousef, George M, Zakhary, Abraam, Rotondo, Fabio, Saad, Gina, Nguyen, Vy‐nhan, Kidanewold, Wondwossen, Streutker, Catherine, Rowsell, Corwyn, Hamdani, Malek, and Saleeb, Rola M

Subjects
*RENAL cell carcinoma, *GENE expression, *NUCLEIC acid hybridization, *PROGRESSION-free survival, *IN situ hybridization
Abstract

Aims: Papillary renal cell carcinoma (PRCC) histologic subtyping is no longer recommended in the 2022 WHO classification. Currently, WHO/ISUP nucleolar grade is the only accepted prognostic histologic parameter for PRCC. ABCC2, a renal drug transporter, has been shown to significantly predict outcomes in PRCC. In this study we evaluated the prognostic significance of ABCC2 IHC staining patterns in a large, multi‐institutional PRCC cohort and assessed the association of these patterns with ABCC2 mRNA expression. Methods and results: We assessed 254 PRCCs for ABCC2 IHC reactivity patterns that were stratified into negative, cytoplasmic, brush‐border <50%, and brush‐border ≥50%. RNA in situ hybridization (ISH) was used to determine the transcript level of each group. Survival analysis was performed with SPSS and GraphPad software. RNA‐ISH showed that the ABCC2 group with any brush‐border staining was associated with a significant increase in the transcript level, when compared to the negative/cytoplasmic group (P = 0.034). Both ABCC2 groups with brush‐border <50% (P = 0.024) and brush‐border ≥50% (P < 0.001) were also associated with worse disease‐free survival (DFS) in univariate analysis. Multivariate analysis showed that only ABCC2 IHC brush‐border (<50% and ≥50%) reactivity groups (P = 0.037 and P = 0.003, respectively), and high‐stage disease (P < 0.001) had a DFS of prognostic significance. In addition, ABCC2 brush‐border showed significantly worse DFS in pT1a (P = 0.014), pT1 (P = 0.013), ≤4 cm tumour (P = 0.041) and high stage (P = 0.014) groups, while a similar analysis with high WHO/ISUP grade in these groups was not significant. Conclusion: ABCC2 IHC brush‐border expression in PRCC correlates with significantly higher gene expression and also independently predicts survival outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

230. Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium

Author

Fleshner, Neil E., primary, Kapusta, Linda, additional, Donnelly, Bryan, additional, Tanguay, Simon, additional, Chin, Joseph, additional, Hersey, Karen, additional, Farley, Anne, additional, Jansz, Ken, additional, Siemens, D. Robert, additional, Trpkov, Kiril, additional, Lacombe, Louis, additional, Gleave, Martin, additional, Tu, Dongsheng, additional, and Parulekar, Wendy R., additional

Published
2011
Full Text
View/download PDF

233. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Author

UCL - MD/MNOP - Département de morphologie normale et pathologique, Racusen, Lorraine C, Colvin, Robert B, Solez, Kim, Mihatsch, Michael J, Halloran, Philip F, Campbell, Patricia M, Cecka, Michael J, Cosyns, Jean-Pierre, Demetris, Anthony J, Fishbein, Michael C, Fogo, Agnes, Furness, Peter, Gibson, Ian W, Glotz, Denis, Hayry, Pekka, Hunsickern, Lawrence, Kashgarian, Michael, Kerman, Ronald, Magil, Alex J, Montgomery, Robert, Morozumi, Kunio, Nickeleit, Volker, Randhawa, Parmjeet, Regele, Heinz, Seron, Daniel, Seshan, Surya, Sund, Stale, Trpkov, Kiril, UCL - MD/MNOP - Département de morphologie normale et pathologique, Racusen, Lorraine C, Colvin, Robert B, Solez, Kim, Mihatsch, Michael J, Halloran, Philip F, Campbell, Patricia M, Cecka, Michael J, Cosyns, Jean-Pierre, Demetris, Anthony J, Fishbein, Michael C, Fogo, Agnes, Furness, Peter, Gibson, Ian W, Glotz, Denis, Hayry, Pekka, Hunsickern, Lawrence, Kashgarian, Michael, Kerman, Ronald, Magil, Alex J, Montgomery, Robert, Morozumi, Kunio, Nickeleit, Volker, Randhawa, Parmjeet, Regele, Heinz, Seron, Daniel, Seshan, Surya, Sund, Stale, and Trpkov, Kiril

Abstract

Antibody-mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent outcomes even in patients highly sensitized to the donor prior to transplant. It has become critical to develop standardized criteria for the pathological diagnosis of AbAR. This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001. This classification represents a working formulation, to be revisited as additional data accumulate in this important area of renal transplantation.

Published
2003

236. Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic

Author

Thirukkumaran, Chandini M., primary, Nodwell, Michael J., additional, Hirasawa, Kensuke, additional, Shi, Zhong-Qiao, additional, Diaz, Roman, additional, Luider, Joanne, additional, Johnston, Randal N., additional, Forsyth, Peter A., additional, Magliocco, Anthony M., additional, Lee, Patrick, additional, Nishikawa, Sandra, additional, Donnelly, Bryan, additional, Coffey, Matt, additional, Trpkov, Kiril, additional, Fonseca, Kevin, additional, Spurrell, Jason, additional, and Morris, Don G., additional

Published
2010
Full Text
View/download PDF

242. Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens

Author

Evans, Andrew J., primary, Henry, Pauline C., additional, Van der Kwast, Theodorus H., additional, Tkachuk, Douglas C., additional, Watson, Kemp, additional, Lockwood, Gina A., additional, Fleshner, Neil E., additional, Cheung, Carol, additional, Belanger, Eric C., additional, Amin, Mahul B., additional, Boccon-Gibod, Liliane, additional, Bostwick, David G., additional, Egevad, Lars, additional, Epstein, Jonathan I., additional, Grignon, David J., additional, Jones, Edward C., additional, Montironi, Rodolfo, additional, Moussa, Madeleine, additional, Sweet, Joan M., additional, Trpkov, Kiril, additional, Wheeler, Thomas M., additional, and Srigley, John R., additional

Published
2008
Full Text
View/download PDF

247. Renal Leiomyoma.

Author

Patil, Pallavi A., McKenney, Jesse K., Trpkov, Kiril, Hes, Ondrej, Montironi, Rodolfo, Scarpelli, Marina, Nesi, Gabriella, Aron, Manju, Sangoi, Ankur R., Gattuso, Paolo, and Magi-Galluzzi, Cristina

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results